BriaCell Therapeutics Reports Progress in Phase 3 Metastatic Breast Cancer Trial
Key Insights
BriaCell Therapeutics reported an operating loss of $(5.15) million, alongside a net loss of $(5.83) million, influenced by fair value changes in warrant liability.
The company's pivotal Phase 3 study of Bria-IMT™ (search) in metastatic breast cancer (search) is actively enrolling patients across 35 clinical sites.
BriaCell is also advancing its Bria-OTS™ personalized immunotherapy, with the first patient dosed in a Phase 1/2 study, marking a key milestone.
BriaCell Therapeutics Corp. (search), a biotechnology company focused on developing immunotherapies for cancer (search), has released its Form 10-Q report for the third quarter of 2024, highlighting progress in its Bria-IMT™ (search) and Bria-OTS™ immunotherapy programs. The company is currently prioritizing its pivotal Phase 3 study of Bria-IMT™ in advanced breast cancer. As of October 15, 2024, 35 clinical sites are actively enrolling patients for the Phase 3 study. The company has also dosed the first patient in a Phase 1/2 study of Bria-OTS™ personalized immunotherapy.
Financial Overview
The report indicates an operating loss of $(5.15) million, reflecting a decrease in operating expenses compared to the previous year. The net loss for the period was $(5.83) million, compared to a gain of $5.96 million in the same period of 2023, primarily due to changes in the fair value of the warrant liability. The net loss per share attributable to BriaCell was $(0.22), compared to a gain of $0.38 in the same period of 2023.
Bria-IMT™ Phase 3 Trial
The pivotal Phase 3 study of Bria-IMT™ (search) in advanced breast cancer (search) is a key focus for BriaCell. The trial is designed to evaluate the efficacy and safety of Bria-IMT™ in combination with an immune checkpoint inhibitor (search). Enrollment is ongoing across 35 active clinical sites. BriaCell aims to achieve full approval and marketing authorization for Bria-IMT™ in metastatic breast cancer (search) patients, contingent on positive results from this pivotal study.
Bria-OTS™ Phase 1/2 Study
BriaCell is also progressing with its Bria-OTS™ personalized immunotherapy. The first patient has been dosed in a Phase 1/2 study. This study will evaluate the safety and preliminary efficacy of Bria-OTS™ in patients with advanced cancer (search). The completion of the Phase 1/2a trial has allowed for a reallocation of resources to the ongoing Phase 1/2 study.
Operational Adjustments
BriaCell has optimized its expenditures for the pivotal Phase 3 trial, resulting in a decrease in research and development costs. The company has also adjusted its resource allocation, leading to a slight decrease in wages and salaries. These adjustments are aimed at maximizing efficiency and focusing resources on the most promising clinical programs.